Absci Corp. (ABSI)
8.80
-0.04
(-0.45%)
USD |
NASDAQ |
Sep 02, 16:00
8.81
+0.01
(+0.11%)
Pre-Market: 08:13
Absci Research and Development Expense (TTM) : 86.49M for June 30, 2026
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| June 30, 2026 | 86.49M |
| March 31, 2026 | 84.33M |
| December 31, 2025 | 81.42M |
| September 30, 2025 | 74.45M |
| June 30, 2025 | 73.18M |
| March 31, 2025 | 67.99M |
| December 31, 2024 | 63.86M |
| September 30, 2024 | 57.25M |
| June 30, 2024 | 50.30M |
| March 31, 2024 | 47.15M |
| December 31, 2023 | 47.57M |
| September 30, 2023 | 47.11M |
| Date | Value |
|---|---|
| June 30, 2023 | 51.61M |
| March 31, 2023 | 55.74M |
| December 31, 2022 | 58.91M |
| September 30, 2022 | 63.36M |
| June 30, 2022 | 58.56M |
| March 31, 2022 | 53.36M |
| December 31, 2021 | 44.59M |
| September 30, 2021 | 33.42M |
| June 30, 2021 | 25.38M |
| March 31, 2021 | 16.59M |
| December 31, 2020 | 11.45M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| Twist Bioscience Corp. | 71.86M |
| Prime Medicine, Inc. | 146.20M |
| Beam Therapeutics, Inc. | 408.66M |
| Tenax Therapeutics, Inc. | 45.26M |
| Manhattan Scientifics, Inc. | -- |